Skip to content

PHARMA-BIO SERV, INC.: 10-Q filed 2021-06-14

What PHARMA-BIO SERV, INC. reported in its quarterly report filed 2021-06-14 (fiscal Q2 2021): 35 published measures, 124 facts as tagged in accession 0001654954-21-006857.

This filing

Form
10-Q (quarterly report)
Filed
2021-06-14
Fiscal period
fiscal Q2 2021
Accession
0001654954-21-006857 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMA-BIO SERV, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-04-3027,898,943USD
At 2020-10-3129,918,746USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-04-306,349,992USD
At 2020-10-317,202,085USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-04-3021,548,951USD
At 2021-01-3121,292,511USD
At 2020-10-3122,716,661USD
At 2020-04-3021,801,661USD
At 2020-01-3121,132,403USD
At 2019-10-3120,607,506USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-04-3016,066,487USD
At 2021-01-3118,988,339USD
At 2020-10-3117,137,924USD
At 2020-04-3015,581,997USD
At 2020-01-3115,254,752USD
At 2019-10-3115,490,174USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-02-01 to 2021-04-30240,271USD89
2020-11-01 to 2021-04-30508,303USD181
2020-11-01 to 2021-01-31268,032USD92
2020-02-01 to 2020-04-30687,561USD90
2019-11-01 to 2020-04-301,214,461USD182
2019-11-01 to 2020-01-31526,900USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-02-01 to 2021-04-30-1,185,418USD89
2020-11-01 to 2021-04-30-597,232USD181
2020-02-01 to 2020-04-30-1,556,707USD90
2019-11-01 to 2020-04-30-41,688USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-02-01 to 2021-04-302,048USD89
2020-11-01 to 2021-04-304,616USD181
2020-02-01 to 2020-04-3027,548USD90
2019-11-01 to 2020-04-3038,874USD182

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-02-01 to 2021-04-305,041,666USD89
2020-11-01 to 2021-04-309,529,975USD181
2020-02-01 to 2020-04-305,647,767USD90
2019-11-01 to 2020-04-3010,260,934USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-02-01 to 2021-04-30-1,791,592USD89
2020-11-01 to 2021-04-30-1,794,443USD181
2020-02-01 to 2020-04-301,928,961USD90
2019-11-01 to 2020-04-30199,265USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-02-01 to 2021-04-3055,523USD89
2020-11-01 to 2021-04-301,302,955USD181
2020-02-01 to 2020-04-30-15,548USD90
2019-11-01 to 2020-04-30-26,874USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-04-3020,304,927USD
At 2020-10-3121,523,990USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2021-02-01 to 2021-04-3023,029,215shares89
2020-11-01 to 2021-04-3023,019,765shares181
2020-02-01 to 2020-04-3023,001,627shares90
2019-11-01 to 2020-04-3023,002,745shares182

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2021-02-01 to 2021-04-3023,209,118shares89
2020-11-01 to 2021-04-3023,181,347shares181
2020-02-01 to 2020-04-3023,029,203shares90
2019-11-01 to 2020-04-3023,025,958shares182

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-02-01 to 2021-04-3045,598USD89
2020-11-01 to 2021-04-3099,089USD181
2020-02-01 to 2020-04-3081,407USD90
2019-11-01 to 2020-04-30136,702USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-04-30131,766USD
At 2020-10-31217,572USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-02-01 to 2021-04-3011,430USD89
2020-11-01 to 2021-04-3022,860USD181
2020-11-01 to 2021-01-3111,430USD92
2020-02-01 to 2020-04-3011,430USD90
2019-11-01 to 2020-04-3022,860USD182
2019-11-01 to 2020-01-3111,430USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-02-01 to 2021-04-30264,779USD89
2020-11-01 to 2021-04-30583,900USD181
2020-02-01 to 2020-04-30720,384USD90
2019-11-01 to 2020-04-301,257,143USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-04-3026,740,735USD
At 2020-10-3128,584,218USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-04-303,277,733USD
At 2020-10-313,792,793USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-04-3010,364,675USD
At 2020-10-319,727,591USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2021-02-01 to 2021-04-300USD89
2020-11-01 to 2021-04-300USD181
2020-02-01 to 2020-04-300USD90
2019-11-01 to 2020-04-301,699USD182

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2021-02-01 to 2021-04-301,290,872USD89
2020-11-01 to 2021-04-302,605,982USD181
2020-02-01 to 2020-04-301,868,900USD90
2019-11-01 to 2020-04-303,454,792USD182

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2021-02-01 to 2021-04-303,750,794USD89
2020-11-01 to 2021-04-306,923,993USD181
2020-02-01 to 2020-04-303,778,867USD90
2019-11-01 to 2020-04-306,806,142USD182

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2021-02-01 to 2021-04-301,026,093USD89
2020-11-01 to 2021-04-302,022,082USD181
2020-02-01 to 2020-04-301,148,516USD90
2019-11-01 to 2020-04-302,197,649USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-04-3023,029,215shares
At 2020-10-3123,001,627shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2021-04-30189,145USD
At 2020-10-31160,654USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-04-30756,139USD
At 2020-10-31846,714USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-04-30508,836USD
At 2020-10-31501,489USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-04-30270,303USD
At 2020-10-31270,242USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-02-01 to 2021-04-30285,869USD89
2020-11-01 to 2021-04-30607,392USD181
2020-02-01 to 2020-04-30768,968USD90
2019-11-01 to 2020-04-301,351,163USD182

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2021-02-01 to 2021-04-30245,010USD89
2020-11-01 to 2021-04-30536,794USD181
2020-02-01 to 2020-04-30657,828USD90
2019-11-01 to 2020-04-301,172,994USD182

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2021-02-01 to 2021-04-3018,831USD89
2020-11-01 to 2021-04-3040,255USD181
2020-02-01 to 2020-04-3021,579USD90
2019-11-01 to 2020-04-3042,611USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-02-01 to 2021-04-3021,090USD89
2020-11-01 to 2021-04-3023,492USD181
2020-02-01 to 2020-04-3048,584USD90
2019-11-01 to 2020-04-3094,020USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-02-01 to 2021-04-30552USD89
2020-11-01 to 2021-04-301,404USD181
2020-02-01 to 2020-04-30988USD90
2019-11-01 to 2020-04-302,004USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-02-01 to 2021-04-30797,930USD89
2020-11-01 to 2021-04-30621,066USD181
2020-02-01 to 2020-04-302,262,929USD90
2019-11-01 to 2020-04-301,200,788USD182

Inspect the source

Entity
PHARMA-BIO SERV, INC. / CIK 0001304161
Captured
2026-09-19T11:17:27.241Z
SEC response SHA-256
bc9f33e072a9daa74aa0e8c41fbfef83d107920bc25647db80386f28787f2d49

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001304161.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))